AI Analysis
AI-generated analysis. Always verify with the original filing.
BioXcel Therapeutics announced the completion of an updated market opportunity assessment for IGALMI in the at-home setting, informed by the SERENITY At-Home clinical study. The company submitted a supplemental New Drug Application last month seeking FDA approval for this use.
Key Takeaways
1The company submitted a supplemental New Drug Application (sNDA) last month seeking FDA approval for IGALMI for at-home use in treating acute agitation associated with bipolar disorders or schizophrenia.
2Market research identified approximately 2.3 million treated bipolar disorder and schizophrenia patients experiencing frequent episodes of acute agitation in the at-home setting in the United States.
3Up to 1.8 million of these patients may be eligible for IGALMI treatment, representing up to 86 million addressable annual episodes that may require treatment.
4Prescribers reported moderate to high interest in IGALMI for at-home use, projecting use in approximately 70% of their schizophrenia and bipolar disorder patients, regardless of agitation severity.
5Prescribers anticipated IGALMI would most frequently replace benzodiazepines, which may cause dependence.
6Payers indicated expectations for broad formulary coverage with standard adjudication controls.